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Background. Transient neurologic symptoms (TNSs) can be distressing for patients and providers following uneventful spinal
anesthesia. Spinal mepivacaine may be less commonly associated with TNS than lidocaine; however, reported rates of TNS with
intrathecal mepivacaine vary considerably. Materials and Methods. We conducted a retrospective cohort study reviewing the
internal medical records of surgical patients who underwent mepivacaine spinal anesthesia at Toronto Western Hospital over the
last decade to determine the rate of TNS. We deﬁned TNS as new onset back pain that radiated to the buttocks or legs bilaterally.
Results. We found one documented occurrence of TNS among a total of 679 mepivacaine spinal anesthetics (0.14%; CI:
0.02–1.04%) that were performed in 654 patients. Conclusion. Our retrospective data suggest that the rate of TNS associated with
mepivacaine spinal anesthesia is lower than that previously reported in the literature.
1. Introduction
Transient neurologic symptoms (TNSs), characterized by low
back pain that radiates to the buttocks or legs after recovering
from spinal anesthesia [1, 2], can be distressing to patients and
providers. TNS typically appears within 24 hours of spinal
anesthesia, lasts 2–5 days, and resolves completely without
sequelae [2]. Because TNS is traditionally associated with in-
trathecal lidocaine,mepivacaine has been the local anesthetic of
choice for short-acting spinal anesthesia at our institution for
over a decade. While TNS following mepivacaine occurs less
frequently compared to similar doses of lidocaine [3, 4], varied
rates of TNS have been reported following mepivacaine spinal
anesthesia. Previous small randomized trials examining pa-
tients undergoing isobaric intrathecal mepivacaine anesthesia
for knee arthroscopy surgery have reported rates of TNS as
high as 7.5% [3, 5–8]; however, intraoperative positioning for
this procedure has been associated with an increased risk of
TNS [1, 9]. It is our anecdotal experience that TNS following
intrathecal mepivacaine is rare, occurring far less than the 6.4%
incidence reported in one large prospective cohort of knee
arthroscopy patients [9]. *erefore, we undertook this retro-
spective cohort study to understand the rate of TNS reported
among surgical patients who underwent spinal anesthesia with
isobaric mepivacaine at Toronto Western Hospital (TWH)
over the last 10 years. We hypothesized that TNS following
isobaric mepivacaine spinal anesthesia is rare.
2. Materials and Methods
Following the University Health Network ethics approval,
we conducted a retrospective cohort study of consecutive
Hindawi
Anesthesiology Research and Practice
Volume 2018, Article ID 1901426, 5 pages
https://doi.org/10.1155/2018/1901426
patients who received spinal anesthesia with 1.5% or 2%
isobaric mepivacaine for elective surgery at TWH between
January 1, 2006 and March 31, 2017. We adhered to the
STROBE recommendations for the design and reporting of
observational studies [10].
We identiﬁed all mepivacaine spinal anesthetics by
searching our regional anesthesia database, which captures
data for all neuraxial blocks performed in the block pro-
cedure room at our institution. Patients who received
multiple mepivacaine spinal anesthetics for more than one
operative procedure in separate encounters during the study
period and patients who received rescue spinal anesthesia
using mepivacaine following failed spinal anesthesia with
bupivacaine during the same encounter were both included.
All spinal anesthetics were performed by a regional anes-
thesia resident or fellow under direct supervision of the at-
tending anesthesiologist or by the attending anesthesiologist.
*e dose and concentration of mepivacaine, along with any
additives, were administered at the discretion of the attending
anesthesiologist. Since 1.5% mepivacaine is not commercially
available in Canada, this concentrationwas achieved by diluting
2% mepivacaine hydrochloride (Carbocaine® 2%, Hospira,
Montreal, Canada) with preservative-free normal saline.
It is our institutional practice that any patient who de-
velops neurologic symptoms following neuraxial anesthesia,
including TNS, postdural puncture headache, and meningeal,
neuropathic, or radicular symptoms, is referred to our anes-
thesiology department for immediate evaluation and man-
agement. Severe cases or patients at risk of acute deterioration
are referred to the emergency department and/or for urgent
neurosurgical consultation.
For each mepivacaine spinal anesthetic administered, the
corresponding patient’s internal medical record was reviewed
for any documented indication of TNS postoperatively. We
deﬁned TNS as new onset back pain radiating to the buttocks
or legs bilaterally [1, 2]. Speciﬁcally, we reviewed the initial
surgical service postoperative follow-up note (hospital visit
typically scheduled 2–6 weeks postoperatively); any post-
operative anesthetic, medical, or surgical consultations; and
any postoperative emergency room visit records. For patients
who were unanticipatedly admitted to the hospital, the in-
patient surgical service notes were reviewed for evidence of
TNS. Patients for whom the medical record did not include
any postoperative follow-up notes, consultation entries, or
emergency records were excluded from the analyses.
2.1. Analysis. Descriptive statistics were generated for the
entire sample using counts and frequencies for categorical
variables and means, medians, standard deviations, and
interquartile ranges for continuous variables.*e distribution
of continuous variables was assessed using the Shapiro–Wilk
test of normality; none of the continuous variables were
normally distributed, and medians with interquartile ranges
are therefore reported. We describe the cases developing the
outcome, and the absolute risk of developing the outcome
with 95% conﬁdence intervals is reported. In a secondary
analysis, the characteristics of excluded patients were de-
scriptively compared with those comprising the primary
cohort. Statistical analyses were performed using SAS
University Edition 9.4 (Cary, NC, USA).
3. Results
A total of 679 mepivacaine spinal anesthetics were per-
formed in 654 patients. Twenty-two patients (3.3%) un-
derwent multiple mepivacaine spinal anesthetics, among
whom 19 (2.9%) received twomepivacaine spinal anesthetics
and 3 (0.4%) received three mepivacaine spinal anesthetics,
each in separate encounters. Twenty-four patients (3.6%)
received a rescue spinal anesthetic using isobaric mepiva-
caine following a failed spinal anesthetic with isobaric
bupivacaine (5–15mg) during the same encounter. Figure 1
details the identiﬁcation process for the present cohort.
Our cohort characteristics are presented in Table 1.
Among the 679 spinal anesthetics, 606 (89%) were per-
formed using 2% mepivacaine and the remaining 73 (11%)
were performed with 1.5% mepivacaine. 220 (32%) and six
(0.9%) spinal anesthetics included intrathecal fentanyl (5–
25mcg) or morphine (50mcg), respectively, in an admixture
with isobaric mepivacaine. Four (0.6%) spinal anesthetics
included hyperbaric bupivacaine (3.75–7.5mg) in an ad-
mixture with isobaric mepivacaine for added baricity.
*e spinal anesthesia procedures were most commonly
performed in the sitting position (n � 671, 99%), using
a midline approach (n � 660, 97%) with a 25 gauge (n � 641,
1018 mepivacaine spinal anaesthetics
identiﬁed during the January 2006–March
2017 period
679 complete records
(n = 679)
654 unique patients
included in analysis
339 records were excluded 
due to incomplete or
missing data
608 patients: single mepivacaine spinal
(n = 608)
24 patients: rescue mepivacaine spinal
(n = 24)
19 patients: 2 mepivacaine spinals /
patient (n = 38)
3 patients: 3 mepivacaine spinals / patient
(n = 9)
(i)
(ii)
(iii)
(iv)
Figure 1: Flow diagram detailing the identiﬁcation process for the
present cohort of mepivacaine spinal anesthetics.
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94%) Whitacre needle (n � 663, 98%). Paresthesia during
intrathecal injection was reported during a single spinal
anesthetic, while pain upon intrathecal injection was not
reported during any spinal anesthetic. No patients experi-
enced any new postoperative motor deﬁcits.
*e median time to the initial postoperative surgical visit
was 20 days (IQR 13–47 days). One patient was referred to
our anesthesia department for consultation regarding post-
operative neurological symptoms. None of the remaining 653
patients (who underwent 677 mepivacaine spinal anesthetics
in total) received postoperative consultation by any medical
or surgical service at our institution, none were referred to our
emergency room, and none were readmitted postoperatively.
3.1. Primary Outcome: TNS. Among the 679 mepivacaine
spinal anesthetics performed, a single occurrence of TNS
(0.14%; CI: 0.02–1.04%) was found in a 75-year-old female
patient (BMI 27) undergoing ankle hardware removal
surgery, who received spinal anesthesia with 2.5mL of 2%
mepivacaine at the L4-L5 level. No pain or paresthesia was
reported during intrathecal injection. Of note, this patient
appeared in our dataset twice, as she received a mepivacaine
spinal anesthetic in a separate encounter for knee arthros-
copy 43 months prior with no complications, but developed
TNS following second exposure.
In secondary analyses (Table 2), the characteristics of
excluded patients did not qualitatively diﬀer from the pri-
mary study cohort.
4. Discussion
Our single-institution retrospective cohort study suggests
that the reported rate of TNS following spinal anesthesia
with isobaric mepivacaine is very low. Our large cohort of
mepivacaine spinal anesthetics allowed for addressing some
important shortcomings in previous small randomized
trials, wherein a wide range of 0–7.5% rates of TNS have
been observed [3, 5–8].*e majority of previously published
studies were small, each including less than 100 patients
[3, 5–8]; and several of these studies employed a combined
spinal-epidural technique which may have obscured the
relationship between spinal mepivacaine and TNS [6–9].
Further, almost all previous studies investigating the asso-
ciation between spinal mepivacaine and TNS were con-
ducted in patients undergoing arthroscopic knee surgery
[3, 5–9], the intraoperative surgical position for which has
been associated with an increased risk of TNS [9]. In our
study, 38% of mepivacaine spinal anesthetics were
Table 1: Cohort characteristics (n � 679 mepivacaine spinal
anesthetics).
Age (in years; median, IQR) 61 71
Sex (n male, %) 336 49%
Height (cm; median, IQR) 168 161–177
Weight (kg; median, IQR) 86 71–100
BMI (kg/m2; median, IQR) 29 25–35
Mepivacaine volume (mL; n, %)≤1.5 81 13%
1.6–2.0 64 9%
2.1–2.5 178 26%
2.6–3.0 336 49%>3 20 3%
Spinal position (n, %)
Sitting 670 99%
Lateral 9 1%
Spinal approach (n, %)
Midline 660 97%
Paramedian 19 3%
Spinal level (n, %)
L2-L3 58 8%
L3-L4 466 69%
L4-L5 153 23%
Not deﬁned 2 0%
Spinal needle type (n, %)
Quincke 6 1%
Sprotte 10 1%
Whitacre 663 98%
Spinal needle Gauge (n, %)<24 26 4%
25 641 94%
27 11 2%
Not deﬁned 1 0%
Surgical procedure (n, %)
General surgery
Inguinal hernia repair 4 1%
Orthopedics
Ankle
Arthroscopy 29 4%
Fusion 2 0%
Hardware removal 56 8%
ORIF 45 7%
Tendon repair 24 4%
Foot
1st MTP surgery 36 5%
Reconstruction 60 9%
Hip
Arthroplasty 4 0%
Arthroscopy 6 1%
Knee
Arthroplasty 68 10%
Arthroscopy
Bilateral 31 5%
Unilateral 226 33%
Hardware removal 39 6%
ORIF 13 2%
Plastic surgery
Soft tissue surgery∗ 10 1%
Urology
Cystoscopy or cystolithopaxy 12 2%
TURP or TURBT 14 2%
Intraoperative position (n, %)
Knee arthroscopy 257 38%
Lateral 17 2%
Table 1: Continued.
Lithotomy 27 4%
Prone 7 1%
Supine 371 55%
BMI� body mass index; MTP�metatarsal-phalangeal joint; ORIF� open
reduction internal ﬁxation; TURBT� transurethral resection of bladder
tumor; TURP� transurethral resection of the prostate; ∗carcinoma exci-
sion, hematoma evacuation, and skin graft excision.
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performed for knee arthroscopy procedures; the remaining
spinal anesthetics were performed for lower extremity or-
thopedic and lower abdominal procedures. *is variety of
surgical procedures may have contributed to the low rate of
TNS observed herein. Our low rate of TNS may also have
been impacted by contemporary anesthetic practice, in-
cluding the adoption of multimodal analgesia and pro-
phylactic antiemetic medications as evidence supporting
their use became available. It is possible that the increasingly
routine use of nonsteroidal antiinﬂammatory drugs such as
ketorolac administered for preventive analgesia and the
inherent antiinﬂammatory properties of dexamethasone
administered for postoperative nausea and vomiting may
prevent and/or mask symptoms of TNS, and at least partially
account for our low reported rates of TNS. *e latter not-
withstanding, the results of this retrospective review un-
derscore that TNS following mepivacaine spinal anesthesia
has not posed a clinical challenge to our regional anesthesia
teaching program over the last decade.
Under the conditions for detection of TNS in the present
study, a single case was identiﬁed. *e single observed case of
TNS occurred in an elderly patient who received mepivacaine
spinal anesthesia for ankle hardware removal after 43months of
having received mepivacaine spinal anesthesia for knee ar-
throscopy.While advanced age is independently associatedwith
TNS [9], the eﬀect of multiple exposures to intrathecal mepi-
vacaine or rescue mepivacaine spinal anesthesia has not been
extensively investigated. Unfortunately, although our cohort
captured the greatest number of patients receiving multiple
isobaric mepivacaine spinal anesthetics to date, the single ob-
served occurrence of TNS precluded examining statistical as-
sociations of previously identiﬁed risk factors for TNS such as
age [9] or novel considerations such as multiple exposures.
Our results are subject to several limitations. First, our
study comprised all mepivacaine spinal anesthetics conducted
in a single-academic tertiary care hospital in a manner re-
ﬂective of institutional clinical practice. Similar studies at
centres with diﬀering case mixes are necessary to generalize
our ﬁndings to other practice settings. Second, due to the
retrospective nature of our study, there is considerable po-
tential for underreporting. It is possible that minor episodes
resolved spontaneously and may not have been recalled,
reported, and/or documented. Given that TNS is routinely
discussed and disclosed during our informed consent process
prior to performing spinal anesthesia using mepivacaine, it is
also possible that even moderate-or-severe TNS symptoms
were appropriately disregarded and unreported by patients.
Further, we excluded 339mepivacaine spinal anesthetics from
our analyses due to incomplete or missing postoperative data,
most likely because follow-up occurred in a private clinic.
However, none of these patients were referred to our anes-
thesia department for consultation, none received any other
medical or surgical consultation, none were readmitted, and
none visited our emergency room postoperatively. It is also
noteworthy that the characteristics of excluded patients (Table 2)
did not appreciably diﬀer from the present study cohort. In
addition, though our dataset includes patients undergoing
several surgical procedures, given the single case of TNS
Table 2: Characteristics of excluded records (n � 339 mepivacaine
spinal anesthetics).
Age (in years; median, IQR) 54 44–63
Sex (n male, %) 190 56%
Height (cm; median, IQR) 171 164–179
Weight (kg; median, IQR) 93 74–110
BMI (kg/m2; median, IQR) 31 25–38
Mepivacaine volume (mL; n, %)≤1.5 22 7%
1.6–2.0 17 5%
2.1–2.5 82 24%
2.6–3.0 213 63%>3 5 1%
Spinal position (n, %)
Sitting 338 100%
Lateral 1 0%
Spinal approach (n, %)
Midline 331 98%
Paramedian 8 2%
Spinal level (n, %)
L2-L3 25 7%
L3-L4 232 68%
L4-L5 79 24%
Not deﬁned 3 1%
Spinal needle type (n, %)
Quincke 2 0%
Sprotte 6 2%
Whitacre 331 98%
Spinal needle Gauge (n, %)<24 13 4%
25 323 95%
27 1 0%
Not deﬁned 2 1%
Surgical procedure (n, %)
General Surgery
Inguinal hernia repair 3 1%
Orthopedics
Ankle
Arthroscopy 40 12%
Fusion 7 2%
Hardware removal 26 8%
ORIF 36 11%
Tendon repair 11 3%
Foot
1st MTP surgery 6 2%
Reconstruction 10 3%
Hip
Arthroplasty 0 0%
Arthroscopy 4 1%
Knee
Arthroplasty 33 10%
Arthroscopy
Bilateral 7 2%
Unilateral 122 36%
Hardware removal 11 3%
ORIF 10 3%
Plastic Surgery
Soft tissue surgery∗ 5 2%
Urology
Cystoscopy or cystolithopaxy 2 0%
TURP or TURBT 6 2%
Intraoperative position (n, %)
Knee arthroscopy 129 38%
Lateral 8 2%
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observed, we are unable to statistically verify known risk factors
for TNS, such as lithotomy position and obesity [1].
5. Conclusion
A large cohort comprising a decade of experience with
isobaric mepivacaine for short-acting spinal anesthesia at
our institution suggests that the rate of TNS is lower than
that previously reported in the literature. Practically, TNS
following mepivacaine spinal anesthesia has not posed
a clinical challenge to our regional anesthesia teaching
program over the last decade.
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